Prioritize next-generation ALK inhibitors with CNS penetration and resistance coverage, supported by molecular testing, differentiated safety, strategic access and KOL-led adoption.Dublin, Oct. 14, ...

In advanced non–small cell lung cancer (NSCLC), molecular testing must be completed in time to guide first-line treatment. Broad molecular profiling is recommended for advanced nonsquamous NSCLC and, ...

Please provide your email address to receive an email when new articles are posted on . Most patients with nonsquamous NSCLC treated at academically-affiliated community clinics received ...

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines all ...

Shiven B. Patel, MD, MBA, discussed strategies for overcoming tissue limits, delays, and rural access gaps in NSCLC biomarker testing at an IVBM event. As moderator of the panel “Precision in Practice ...

PREDAPT Trial Validates RNA-Based Predictive Biomarker Across 1400+ Patients to Inform Immunotherapy Treatment in NSCLC ST. LOUIS, December 17, 2025--(BUSINESS WIRE)--Cofactor Genomics, a leader in ...

This article is based on a poster originally authored by Rania Gaspo, Renaud Burrer, Jérôme Sallette, Amanda Finan-Marchi, and Marie Gérus-Durand. NSCLC (non-small cell lung cancer) treatment is ...

Those questions point to research that is still needed, Nieva says. This includes the role of deintensifying imaging and ...

The discussion transitions to biomarker testing as an essential component of lung cancer diagnosis, with Dr. Florez emphasizing that diagnosis remains incomplete until molecular characterization is ...

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

ROS1-positive non-small cell lung cancer (NSCLC) is a rare subtype of lung cancer that occurs when part of the ROS1 gene fuses with another gene. It affects about 1% to 2% of people with NSCLC and ...

Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer. Xiuning Le, MD, PhD, an associate ...